Treatment Extends Survival Time and Provides New Hope to Patients with Metastatic Liver Tumors

SIR-Spheres microspheres, manufactured by Sirtex, are the only fully FDA PMA approved microspheres for colorectal cancer that has metastasized to the liver.¹

At least 60 percent of the nearly 140,000 Americans diagnosed with colorectal cancer every year will see their cancer spread to the liver,²,³ and most liver tumors cannot be surgically resected. Metastatic liver cancer is often fatal, with up to 90 percent of patients dying from liver failure. Microspheres therapy has emerged as a treatment option for patients with colorectal cancer that has spread to the liver.

SIR-Spheres microspheres are microscopic radioactive spheres that can be delivered by the millions directly to the tumor site. The microspheres contain the radioactive isotope yttrium-90, which delivers beta radiation to the tumor. The microspheres selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy while sparing healthy tissue.

Contact us for more information: 315-234-4686

¹ SIR-Spheres microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine).